A transition from the use of HFA 134a and HFA 227 as propellants in metered dose inhalers (MDIs) to lower global warming potential (LGWP) propellants is in the early stages
Learn more about these LGWP propellants:
Learn more about the transition:
View IPAC-RS’s October 11, 2023 Workshop on the Transition to Low Global Warming Potential Propellants for Metered Dose Inhalers
Recent news about LGWP propellants:
-
Mundipharma and Vectura partner on LGWP reformulation of Flutiform MDI
-
Chiesi initiates Phase 3 trial of HFA 152a version of its Trimbow MDI
-
Bespak spins out from Recipharm, will focus on LGWP transition
-
DDL 2023 highlighted novel technologies
-
Oz-UK adds manufacturing line for MDIs with LGWP propellants
-
Recipharm announces appointment of Simon Gardner as Business Development Specialist, partnership with Oz-UK on LGWP MDIs
-
Kindeva and Koura partner on conversion of existing MDI to HFA 152a
-
FDA contracts with Aptar for LGWP propellant study
-
GSK announces upcoming Phase 3 trials of HFA 152a version of Ventolin salbutamol (albuterol) MDI
-
Honeywell and Recipharm partner on development of MDIs using Solstice Air HFO-1234ze(e) propellant